Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population

Sebastian V. Demyttenaere, Simon Bergman, Thomas Pham, Joel Anderson, Rebecca Dettorre, W. Scott Melvin, Dean J. Mikami

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Methods Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. Results: The study enrolled 26 patients with a mean age of 45 years. The patients included 16women (62%)with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217°, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiringNissen fundoplication, and there was one late death unrelated to the procedure. Conclusion This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow- up evaluation and objective testing are required.

Original languageEnglish (US)
Pages (from-to)854-858
Number of pages5
JournalSurgical Endoscopy and Other Interventional Techniques
Volume24
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Fundoplication
Gastroesophageal Reflux
Population
Length of Stay
Esophageal Motility Disorders
Hiatal Hernia
Barrett Esophagus
Anesthesiology
Body Mass Index
Quality of Life
Equipment and Supplies
Therapeutics

Keywords

  • EsophyX
  • Gastroesophageal reflux disease (GERD)
  • Transoral incisionless fundoplication

ASJC Scopus subject areas

  • Surgery

Cite this

Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. / Demyttenaere, Sebastian V.; Bergman, Simon; Pham, Thomas; Anderson, Joel; Dettorre, Rebecca; Melvin, W. Scott; Mikami, Dean J.

In: Surgical Endoscopy and Other Interventional Techniques, Vol. 24, No. 4, 04.2010, p. 854-858.

Research output: Contribution to journalArticle

Demyttenaere, Sebastian V. ; Bergman, Simon ; Pham, Thomas ; Anderson, Joel ; Dettorre, Rebecca ; Melvin, W. Scott ; Mikami, Dean J. / Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. In: Surgical Endoscopy and Other Interventional Techniques. 2010 ; Vol. 24, No. 4. pp. 854-858.
@article{4f25dae764e54785bc5d88bd8fd8b11f,
title = "Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population",
abstract = "Background: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Methods Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. Results: The study enrolled 26 patients with a mean age of 45 years. The patients included 16women (62{\%})with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217°, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68{\%} of the patients were still taking antireflux medications, 21{\%} had reduced their dose by half. Three patients had persistent symptoms requiringNissen fundoplication, and there was one late death unrelated to the procedure. Conclusion This study represents an initial single-institution experience with EsophyX. According to the findings, 53{\%} of the patients had either discontinued their antireflux medication (32{\%}) or had decreased their dose by half (21{\%}). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow- up evaluation and objective testing are required.",
keywords = "EsophyX, Gastroesophageal reflux disease (GERD), Transoral incisionless fundoplication",
author = "Demyttenaere, {Sebastian V.} and Simon Bergman and Thomas Pham and Joel Anderson and Rebecca Dettorre and Melvin, {W. Scott} and Mikami, {Dean J.}",
year = "2010",
month = "4",
doi = "10.1007/s00464-009-0676-z",
language = "English (US)",
volume = "24",
pages = "854--858",
journal = "Surgical Endoscopy and Other Interventional Techniques",
issn = "0930-2794",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population

AU - Demyttenaere, Sebastian V.

AU - Bergman, Simon

AU - Pham, Thomas

AU - Anderson, Joel

AU - Dettorre, Rebecca

AU - Melvin, W. Scott

AU - Mikami, Dean J.

PY - 2010/4

Y1 - 2010/4

N2 - Background: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Methods Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. Results: The study enrolled 26 patients with a mean age of 45 years. The patients included 16women (62%)with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217°, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiringNissen fundoplication, and there was one late death unrelated to the procedure. Conclusion This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow- up evaluation and objective testing are required.

AB - Background: EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Methods Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. Results: The study enrolled 26 patients with a mean age of 45 years. The patients included 16women (62%)with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett's esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29-137 min), and the length of hospital stay was 1 day (range, 0-6 days). The postoperative valve circumference was 217°, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34-17; P = 0.002) and Velanovich scores (22-10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiringNissen fundoplication, and there was one late death unrelated to the procedure. Conclusion This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow- up evaluation and objective testing are required.

KW - EsophyX

KW - Gastroesophageal reflux disease (GERD)

KW - Transoral incisionless fundoplication

UR - http://www.scopus.com/inward/record.url?scp=77952493452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952493452&partnerID=8YFLogxK

U2 - 10.1007/s00464-009-0676-z

DO - 10.1007/s00464-009-0676-z

M3 - Article

C2 - 19730949

AN - SCOPUS:77952493452

VL - 24

SP - 854

EP - 858

JO - Surgical Endoscopy and Other Interventional Techniques

JF - Surgical Endoscopy and Other Interventional Techniques

SN - 0930-2794

IS - 4

ER -